Cytomedix Announces Multiple Presentations at the 23rd Annual Symposium on Advanced Wound Care and Wound Healing Society

• The Impact of Autologous Platelet Rich Plasma Gel on Rapid Wound Improvement in the Outpatient Setting Presented by Donna R. Carman, M.D., Phoenix Indian Medical Center, Poster Number CR-020
• Use of Platelet Rich Plasma Gel in Chronic Pressure Ulcers of the Pelvic Region Presented by Jean DeLeon, M.D., Medical Director, Baylor Specialty Hospital, Poster Number CS-021
• The Use of Platelet Rich Plasma and Negative Pressure Wound Therapy in the Treatment of Large Post Surgical Abdominal Wounds Presented by Jean DeLeon, M.D., Medical Director, Baylor Specialty Hospital, Poster Number CS-022
• Use of Platelet Rich Plasma Gel (PRPG) with Negative Pressure Wound Therapy (NPWT) to Treat Surgically Debrided Wounds Presented by Jean DeLeon, M.D., Medical Director, Baylor Specialty Hospital, Poster Number CS- 023
• Efficient Rapid Wound Improvement in the LTAC Setting with Autologous Platelet Rich Plasma Presented by Carelyn Fylling, R.N., M.S.N., Vice President, Professional Services, Cytomedix, Inc., Poster Number CR-038
• Platelet Rich Plasma – A Comparison of Outcomes from Clinical Trials on Chronic Wounds Presented by Laurie M. Rappl, PT, CWS, Cytomedix, Inc., Poster Number IR-051

The SAWC Oral abstract sessions will be held on Sunday, April 18, 2010 from 4:45 p.m. to 5:45 p.m. and Monday, April 19th from 3:30 p.m. to 4:30 p.m. The following oral presentation highlighting Cytomedix’s PRP technology will be delivered at SAWC/WHS.

• Response of Wounds of Spinal Cord Injury Patients to Autologous Platelet Rich Plasma Gel Presented by Laurie M. Rappl, PT, CWS, Cytomedix, Inc.

“This substantial body of data underscores the clinical utility of our AutoloGel System to meaningfully accelerate and enhance the body’s own natural healing process in a variety of exuding wounds, and highlights the versatility of our system’s capabilities in a number of different patient settings,” said Martin Rosendale, Chief Executive Officer of Cytomedix. “In addition to this presentation of these favorable data, we expect select data to be published in peer-reviewed journals starting in the second half of 2010. "

About Cytomedix

Cytomedix is a biotechnology company that develops, sells, and licenses regenerative biological therapies, to primarily address the areas of wound care, inflammation, and angiogenesis. The Company currently markets the AutoloGel™ System, a device for the production of platelet rich plasma (“PRP”) gel derived from the patient’s own blood for use on a variety of exuding wounds; the Angel® Whole Blood Separation System, a blood processing device and disposable products used for separation of whole blood into red cells, platelet poor plasma and platelet rich plasma (“PRP”) in surgical settings; and the activAT® Autologous Thrombin Processing Kit, which produces autologous thrombin serum from platelet poor plasma. The activAT kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovinederived products. The Company is currently pursuing a multi-faceted strategy to penetrate the chronic wound market with its products. Cytomedix is also pursuing opportunities for the application of AutoloGel™ and PRP technology into other markets such as hair transplantation and orthopedics, as well as actively seeking complementary products for the wound care market. The Company also seeks to monetize other product candidates in its pipeline through strategic partnerships, out-licensing, or sale. Most notably is its anti-inflammatory peptide (designated “CT-112”) that has shown promise in pre-clinical testing. Additional information regarding Cytomedix is available at www.cytomedix.com.

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix’s actual results may differ materially due to a number of factors, many of which are beyond Cytomedix’s ability to predict or control, including among others, viability and effectiveness of the Company’s sales approach and overall marketing strategies, the outcome of development or regulatory review of CT-112, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, its ability to successfully commercialize its product in Japan under the terms of the license agreement, and Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.